A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs JS 001 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 26 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History